Key result
Circulating Resolvin D1 is not significantly associated with prevalent carotid stenosis.
Why the study?
Failure to resolve inflammation may contribute to accelerated atherosclerosis in type 2 diabetes, and it was unknown whether circulating Resolvin D1 and Resolvin E1 are associated with carotid atherosclerotic burden or improve discrimination of prevalent carotid stenosis beyond carotid intima-media thickness.
Are circulating serum ELISA-immunoreactive Resolvin D1 and Resolvin E1 concentrations associated with prevalent >=50% carotid stenosis and carotid atherosclerotic burden in adults with type 2 diabetes mellitus?
Cross-Sectional (n=139)
Blinded outcome assessment (ultrasound operator unaware of resolvin results; laboratory personnel unaware of carotid stenosis status)
No
Are circulating serum ELISA-immunoreactive Resolvin D1 and Resolvin E1 concentrations associated with prevalent >=50% carotid stenosis and carotid atherosclerotic burden in adults with type 2 diabetes mellitus?
In adults with type 2 diabetes, higher ELISA-immunoreactive Resolvin D1 was not significantly associated with the binary primary endpoint of >=50% carotid stenosis after multivariable adjustment, though exploratory analyses showed inverse associations with continuous maximum carotid stenosis and cIMT.
Answers are grounded in this paper and cite their sources.
No significant link to binary stenosis; leaves open exploratory ties to continuous carotid measures in type 2 diabetes.
Failure to resolve inflammation may contribute to accelerated atherosclerosis in type 2 diabetes. We investigated whether circulating Resolvin D1 (RvD1) and Resolvin E1 (RvE1), measured by enzyme-linked immunosorbent assay (ELISA), are associated with carotid atherosclerotic burden and improve discrimination of prevalent carotid stenosis beyond carotid intima-media thickness (cIMT). In this single-center cross-sectional study, 139 adults with type 2 diabetes underwent carotid ultrasonography and serum resolvin measurement. The prespecified primary endpoint, ≥ 50% carotid stenosis, was present in 59 participants (42.4%). After adjustment for prespecified confounders, the association of ELISA-immunoreactive RvD1 with the primary endpoint was not statistically significant (prevalence ratio per 1-SD increment 0.72, 95% CI 0.49–1.03; p = 0.074). In exploratory secondary analyses, each 1-SD higher ELISA-immunoreactive RvD1 was associated with an adjusted 6.92%-point lower maximum stenosis (95% CI 2.79–11.05; p = 0.001) and with lower cIMT; ELISA-immunoreactive RvD1 also differed across plaque phenotypes in unadjusted comparisons ( p < 0.001), although phenotype overlapped with stenosis severity. Adding ELISA-immunoreactive RvD1 to the clinical model with cIMT increased the C-statistic by 0.010 (bootstrap 95% CI − 0.003 to 0.038). ELISA-immunoreactive RvE1 showed no statistically significant adjusted association with stenosis, cIMT, or plaque presence. These exploratory findings are hypothesis-generating and require confirmation with validated mass spectrometric measurements.
No takes yet. Share an insight, caveat, or question.
Uyanık et al. (2026) conducted a cross-sectional in Type 2 diabetes mellitus with carotid atherosclerosis (n=139). Circulating ELISA-immunoreactive Resolvin D1 (RvD1) and Resolvin E1 (RvE1) was evaluated on Prevalent clinically significant carotid stenosis (maximum carotid stenosis >=50%) (PR 0.72 per 1-SD increment in RvD1, 95% CI 0.49-1.03, p=0.074). Circulating ELISA-immunoreactive Resolvin D1 was not associated with prevalent >=50% carotid stenosis after multivariable adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: